August 30, 2023

First Ever Hemophilia Patient to Receive Gene Therapy Since FDA Approval



JUNE 20, 2023

GREEN BAY, WI- Wisconsin resident is the first ever hemophilia B patient to receive gene therapy since FDA approval.

“I feel honored to be the first person to participate in this therapy outside of the clinical trials. I am very excited that I am going to be helping to prove that this is a treatment option for individuals with hemophilia B.”-Mason Buxton

HEMGENIX (etranacogene dezaparvovec), manufactured by uniQure Inc. and distributed by CSL Behring LLC, was FDA approved November of 2022 and is for the treatment of adults with Hemophilia B (Factor IX Deficiency) who currently use Factor IX preventative therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Hemophilia B is a genetic bleeding disorder resulting from missing or insufficient levels of blood clotting Factor IX, a protein needed to produce blood clots to stop bleeding. Symptoms can include prolonged or heavy bleeding after an injury, surgery, or dental procedure; in severe cases, bleeding episodes can occur spontaneously without a clear cause. Prolonged bleeding episodes can lead to serious complications, such as bleeding into joints, muscles or internal organs, including the brain. (Commissioner, O. of the (2022) FDA approves first gene therapy to treat adults with hemophilia B, U.S. Food and Drug Administration. Available at:,current%20or%20historical%20life%2Dthreatening (Accessed: 23 May 2023).

Although HEMGENIX is not a cure for Hemophilia B patients, the medical advancement may reduce, if not, eliminate weekly preventative factor replacement and bleeds.

“HEMGENIX is an important addition to the current treatment paradigm and a long-awaited advancement for the hemophilia B community,” said Matthew Ryan, MD, Adult Hematologist and Medical Director at Hemophilia Outreach Center, Green Bay, WI. “This exciting treatment offers patients a chance to live a life without frequent bleeds or the burden of regular infusions. The availability of this new one-time treatment also sparks additional conversations in the community when it comes to treatment options and goals, which is extremely important when managing a life-long condition, as an individual’s needs can change for a variety of reasons.”

“I’m just excited that patients have this new opportunity that will lead to such a better quality of life versus their current prophylaxis treatment! To live a life free from recurrent prophylaxis, not having that anxiety over if they are going to have a bleed or if they have factor with them, not worrying about damage to their joints from breakthrough bleeds….it will be very lifechanging for them.”- Andrea Miller, APNP, Hemophilia Outreach Center.

Recent Posts

Understanding and Managing Von Willebrand Disease

Von Willebrand Disease (VWD) is the most common hereditary bleeding disorder, affecting both men and women. Despite its prevalence, myths and uncertainties surround its management and impact on daily life. This comprehensive guide aims to demystify VWD, offering...

Navigating Medical Treatment for Hemophilia: A Comprehensive Guide

Hemophilia, a rare but significant bleeding disorder, requires nuanced understanding and specialized care. This guide, leveraging insights from the Hemophilia Outreach Center (HOC) and current medical institutions, offers a deep dive into managing hemophilia...

Aging and Bleeding Disorders

As our bleeding disorder population’s life expectancy continues to rise to that of the average American, our patients need to understand that they are at risk for the same disease states that over 50% of all Americans now...

Every Meal, Every Snack, Have a Plant!

Take good care of yourself when away from home whether on the road, at work or at school. Why?  Current evidence suggests that eating more vegetables, fruit, beans, legumes, seeds and nuts will reduce the risk of cardiovascular disease, diabetes, and certain...

FDA approves first gene therapy for hemophilia B

On November 22, 2022, the FDA approved Hemgenix®, an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: Currently use Factor IX (FIX) prophylaxis therapy, or Have current or...

One Dozen ESSENTIAL Tips for College Students

Get a reusable water bottle for both hot and cold beverages. We often get dehydrated, and this can make us feel fatigued. You can flavor water with flavor drops or fruit slices. Fill the bottle with sparkling water, unsweetened tea, or coffee too. If you make...

The Intriguing World of Microbiota

Diet, Microbes, and Your Health In celebration National Nutrition Month, the Hemophilia Outreach Center’s Nutritionist, Jill, would like to share an informative presentation discussing how Microbes (certain bacteria’s) are connected to your health and well-being....

Social Media